Pet Drug Reports

Reported signs

Reported sign · VeDDRA term

Hypocortisolaemia: reports listing this term

521reports listing the term, 2014–20260% of all reports
94reports, 12 months to March 2026100 in the 12 months before
51.8%classed serious, as reportedall reports: 38.6%
100%of these reports concern dogs

521 reports in FDA's animal adverse event database list the term "Hypocortisolaemia": 0% of all reports. It is a VeDDRA term, chosen by the person who coded the report to match what was described.

94 reports listed it in the 12 months to March 2026, close to the 100 of the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases.

By active ingredient, the drugs named most often in those reports are trilostane, oclacitinib and gabapentin. That order mostly follows how many reports each has overall; the table gives the term's share within each drug's own reports as well.

100% of the reports concern dogs. Of reports listing this term that state seriousness, 51.8% were classed as serious; 4.6% record a death or euthanasia among the outcomes.

Drugs named most often in these reports, by active ingredient

Active ingredients recorded for the drugReports listing the termShare of that drug's own reports
Trilostane4233.5%
Oclacitinib270.1%
Gabapentin240.2%
Insulin200.2%
Maropitant160.1%
Prednisone150.2%
Grapiprant130.2%
Pimobendan130.2%
Carprofen120%
Amlodipine111.5%
Bedinvetmab110.1%
Ursodiol111.5%
Afoxolaner100%
Fluralaner100%
Florfenicol + Mometasone furoate + Terbinafine90.2%
Ivermectin + Pyrantel Pamoate90%
Enalapril Maleate80.4%
Famotidine80.3%
Levothyroxine sodium80.3%
Metronidazole80.2%
Dexamethasone70.2%
Trazodone70.4%
Amoxicillin60.1%
Cefpodoxime proxetil60.1%
Diphenhydramine60.1%

Ordered by number of reports, which mostly tracks how many reports a drug has overall. Across the whole database the term appears in 0% of reports. A drug's presence in a report means the animal received it, not that it produced the sign; FDA states that these data cannot be used to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Single ingredients, pooled across combinations

Active ingredientReports listing the termShare of the ingredient's own reports
Trilostane4233.5%
Oclacitinib270.1%
Gabapentin240.2%
Pyrantel Pamoate210%
Insulin200.2%
Maropitant160.1%
Prednisone150.2%
Grapiprant130.2%
Pimobendan130.2%
Afoxolaner120%
Carprofen120%
Amlodipine111.5%
Bedinvetmab110.1%
Ivermectin110%
Moxidectin110%
Ursodiol111.5%
Fluralaner100%
Sarolaner100%
Florfenicol90.1%
Mometasone furoate90.2%
Terbinafine90.1%
Enalapril Maleate80.4%
Famotidine80.3%
Levothyroxine sodium80.3%
Metronidazole80.2%

Species split

Dog100%521

Coloured bar: share of reports listing this term. Grey bar: the species' share of all reports. The term appears in 0.1% of all dog reports.

Trend

0816Apr 2021: 3May 2021: 0Jun 2021: 6Jul 2021: 4Aug 2021: 1Sep 2021: 1Oct 2021: 3Nov 2021: 1Dec 2021: 1Jan 2022: 22022Feb 2022: 5Mar 2022: 4Apr 2022: 4May 2022: 7Jun 2022: 4Jul 2022: 2Aug 2022: 2Sep 2022: 2Oct 2022: 1Nov 2022: 1Dec 2022: 1Jan 2023: 02023Feb 2023: 1Mar 2023: 8Apr 2023: 3May 2023: 6Jun 2023: 4Jul 2023: 9Aug 2023: 6Sep 2023: 6Oct 2023: 7Nov 2023: 12Dec 2023: 10Jan 2024: 32024Feb 2024: 7Mar 2024: 7Apr 2024: 6May 2024: 5Jun 2024: 9Jul 2024: 16Aug 2024: 5Sep 2024: 7Oct 2024: 8Nov 2024: 10Dec 2024: 9Jan 2025: 92025Feb 2025: 8Mar 2025: 8Apr 2025: 10May 2025: 15Jun 2025: 6Jul 2025: 4Aug 2025: 7Sep 2025: 11Oct 2025: 6Nov 2025: 11Dec 2025: 8Jan 2026: 52026Feb 2026: 6Mar 2026: 5

Reports by month FDA received them, five years to March 2026. The newest months are incomplete because FDA posts reports with a delay of three to six months.

0521032014: 120142015: 120152016: 220162017: 1220172018: 9920182019: 3120192020: 3120202021: 2620212022: 3520222023: 7220232024: 9220242025: 10320252026: 162026

Outcomes and ages in these reports

Outcome recorded in the report

Recovered/Normal4.6%24
Recovered with Sequela1.3%7
Ongoing21.3%111
Died1%5
Euthanized3.6%19
Outcome Unknown68.1%355

Age of the animal

Under 1 year1.7%9
1 to 3 years6.3%33
4 to 7 years11.5%60
8 to 11 years40.9%213
12 years and over37%193
Age not given2.5%13
MeasureReports listing this termAll reports
Reports5211,357,245
Classed serious, of reports stating it51.8%38.6%
Death or euthanasia recorded, per 1,000 reports46.163.8

Grey bars and the right-hand column are the whole database. Outcomes are as stated by the reporter and describe the report as a whole, not this term alone.

Questions about "Hypocortisolaemia"

What does "Hypocortisolaemia" mean in an adverse event report?

It is a VeDDRA dictionary term picked to code what the reporter described. The report's free-text description is not published by FDA and is not shown here.

How many reports list hypocortisolaemia?

521 reports through March 2026 (0% of all reports), 94 of them in the latest 12 months.

Which drugs are named most often alongside this term?

By active ingredient: trilostane (423), oclacitinib (27), gabapentin (24), insulin (20) and maropitant (16). Drugs with many reports overall lead almost every term's list. Brands cannot be identified: openFDA masks them.

Which species are involved?

dog (100%).

Does a drug appearing here mean it produced this sign?

No such conclusion can be drawn. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources."

My animal shows this sign. What now?

This site cannot assess an animal. A veterinarian can; for an emergency, contact a veterinary emergency clinic. See the guide on when to call a vet.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Spelling variants of the same VeDDRA term (for example with and without a cross-reference note) are pooled. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.